Genesis IBRC India Ltd
Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.
- Market Cap ₹ 187 Cr.
- Current Price ₹ 144
- High / Low ₹ 185 / 16.6
- Stock P/E
- Book Value ₹ 7.39
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 19.4 times its book value
- Promoter holding is low: 11.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| 4.33 | |
| 4.15 | |
| Operating Profit | 0.18 |
| OPM % | 4.16% |
| 0.01 | |
| Interest | 0.03 |
| Depreciation | 0.09 |
| Profit before tax | 0.07 |
| Tax % | 128.57% |
| -0.03 | |
| EPS in Rs | -0.02 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 81% |
| 3 Years: | 138% |
| 1 Year: | 763% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| Equity Capital | 13.00 |
| Reserves | -3.39 |
| 1.48 | |
| 1.21 | |
| Total Liabilities | 12.30 |
| 2.07 | |
| CWIP | 1.30 |
| Investments | 0.00 |
| 8.93 | |
| Total Assets | 12.30 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| 1.68 | |
| -4.66 | |
| 3.00 | |
| Net Cash Flow | 0.02 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | |
|---|---|
| Debtor Days | 119.70 |
| Inventory Days | 68.92 |
| Days Payable | 17.87 |
| Cash Conversion Cycle | 170.75 |
| Working Capital Days | 399.56 |
| ROCE % |
Documents
Announcements
-
Pre-offer Advertisement and Corrigendum to the Detailed Public Statement
25 Nov - Open offer at ₹7.00 per share for 20.31% voting capital; corrigendum issued.
-
Updates on Open Offer
24 Nov - Announcement text unreadable; insufficient information to determine impact.
-
Updates on Open Offer
22 Nov - Acquirers' ₹7 open offer for 26,40,039 shares (20.31%), opens Nov 26, 2025; closes Dec 09, 2025.
-
Updates on Open Offer
22 Nov - Open offer for 26,40,039 shares (20.31%) at ₹7; tender Nov 26–Dec 09, 2025.
-
Letter of Offer
19 Nov - Open offer announced to acquire 20.31% of voting capital (SEBI SAST), tendering and statutory details included.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1]
a) Aquaculture Probiotic: Proteomix Protein Balanced Gel, Yuccagen Ammonia Controller, Growfast Gen Single Cell Protein, Progutgen Aquaculture Gut Probiotic, Rhodogen PS -Water Probiotic
b) Aqua Feed Supplement: Moultigen Aqua EDTA Aqua Culture, Vitagen C Aqua Culture and Zeo-Gen Multi Mineral Additive Granules from India
c) Aquaculture Water Sanitizer: Sangen- Broad Spectrum Sanitizer
d) Soil Probiotic: Genpro Wat Soil Probiotic
e) Aquaculture: Vibrio Controller In Shrimp Culture